Home > Healthcare > Medical Devices > Medical Supplies > Intrauterine Devices Market
Based on product, the intrauterine devices market share from hormonal IUD segment is poised to depict a CAGR of more than 6.5% over 2023 - 2032. Hormonal IUDs such as Mirena™ and Kyleena™ can be used for up to 5 years without complications. They are regarded as quite safe and are suitable for people with heavy menstrual flow, fibroids, anemia, and endometriosis. In fact, there have been very few instances where users have experienced vaginal bleeding after its insertion. The other benefits of hormonal IUDs include less painful menstrual cycles, low risk of pelvic inflammatory disease (PID), less bleeding, and long-term contraception, among others.
Intrauterine devices market from the 30-34 age group segment is poised to cross over USD 2 billion by 2032, on account of the growing incidences of unwanted pregnancies and abortions among women of this age group. Moreover, at the age of 30, women have a higher chance of successfully conceiving. This, when combined with rising awareness among women about various IUDs and their applications, makes this segment one of the most prominent consumers of the product.
Asia Pacific intrauterine devices market is expected to grow at over 6.5% CAGR through 2032, driven by the growing investments in the region’s healthcare sector. Recently, for the Union Budget of India for 2022-23, over USD 11.28 billion were allocated to the Ministry of Health and Family Welfare (MoHFW). Many governments in the region are taking more efforts to reduce the cost of existing intrauterine devices in the market while also making superior quality IUDs easily accessible, creating a positive outlook for regional market forecasts. U.S. intrauterine Devices industry is poised to grow at over 9.5% CAGR from 2023 to 2032.